Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial (Q33160892)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

23 July 2017

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

23 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

object named as

Hiroyuki Takei

1 reference

Europe PubMed Central

23 July 2017

Norikazu Masuda

1

object named as

Norikazu Masuda

1 reference

Europe PubMed Central

23 July 2017

4

object named as

Hiroji Iwata

1 reference

Europe PubMed Central

23 July 2017

Takayuki Kinoshita

3

object named as

Takayuki Kinoshita

1 reference

Europe PubMed Central

23 July 2017

author name string

Yasuaki Sagara

2

1 reference

Europe PubMed Central

23 July 2017

Seigo Nakamura

5

1 reference

Europe PubMed Central

23 July 2017

Yasuhiro Yanagita

6

1 reference

Europe PubMed Central

23 July 2017

Reiki Nishimura

7

1 reference

Europe PubMed Central

23 July 2017

Hirotaka Iwase

8

1 reference

Europe PubMed Central

23 July 2017

Shunji Kamigaki

9

1 reference

Europe PubMed Central

23 July 2017

Shinzaburo Noguchi

11

1 reference

Europe PubMed Central

23 July 2017

publication date

20 January 2012

1 reference

Europe PubMed Central

23 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

23 July 2017

13

1 reference

Europe PubMed Central

23 July 2017

345-352

1 reference

Europe PubMed Central

23 July 2017

4

1 reference

Europe PubMed Central

23 July 2017

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy in breast cancer: can we define its role?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase in response rate by prolonged treatment with neoadjuvant letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of clinical response after two cycles of primary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970373-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70373-4

1 reference

Europe PubMed Central

23 July 2017

1 reference

Europe PubMed Central

23 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33160892&oldid=1962232713"